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Summary Background: Very few studies have addressed the etiology of community-
acquired pneumonia (CAP) treated in an ambulatory setting.
Methods: Patients were recruited from physicians’ offices and from Emergency
Rooms in Canada. Pneumonia was defined as two or more respiratory symptoms and
signs and a new opacity on chest radiograph interpreted by a radiologist as
pneumonia. Blood and sputum for culture as well as acute and convalescent serum
samples for serology were obtained. Antibodies to Mycoplasma pneumoniae and
Chlamydia pneumoniae were determined using enzyme-linked immunosorbent
assays.
Results: Five hundred and seven patients were enrolled in the study; 419 (82%) had
blood cultures done, seven (1.4%) of which were positive for Streptococcus
pneumoniae; 241 (47.5%) had a sputum processed for culture, 31% of which were
positive for a potential respiratory pathogen. 437 (86.2%) had both acute and
convalescent serum samples obtained, 148 (33.8%) of which gave a positive result.
Overall an etiological diagnosis was made in 48.4% of the patients. M. pneumoniae
accounted for 15% of the cases, C. pneumoniae 12%, S. pneumoniae 5.9% and
Haemophilus influenzae 4.9%.
Conclusions: Despite considerable effort an etiological diagnosis of CAP treated on
an ambulatory basis was made in only half the patients. The most commonly
identified pathogens were M. pneumoniae, C. pneumoniae, S. pneumoniae,
H. influenzae.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Community-acquired pneumonia (CAP) is a common
disease in North America with significant morbidity
and mortality.1–3 About 80% of all patients with CAP
are treated in an ambulatory setting,4 however, we
know very little about the etiology of pneumonia
affecting these patients. Most ambulatory patients
with CAP are seen in their physician’s office and do
not have any diagnostic testing. Indeed in a study of
944 patients with pneumonia treated either in their
physicians office or in an Emergency Room only 8%
had blood cultures, 11% had sputum cultured and
1.3% had acute and convalescent blood samples
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collected for serological testing.5 A randomized
trial of the treatment of pneumonia in ambulatory
setting gave us the opportunity to determine
the etiology of this important subset of patients
with CAP.
Methods
Study design
This was a prospective, randomized, double-blind,
multicentre study to compare the efficacy and
safety of moxifloxacin 400mg PO OD for 10 days,
to clarithromycin 500mg PO BID for 10 days in
the treatment of non-hospitalized patients with
CAP. Patients 18 years of age or older, with two or
more of the following signs and symptoms (fever,
cough, sputum production, pleuritic chest pain,
dyspnea, crackles, bronchial breathing) consistent
with bacterial pneumonia of mild to moderate
severity, not requiring hospitalization (Fine risk
class I–III were enrolled).6 In order to be classified
as having community-acquired pneumonia, patients
had to have radiographic evidence of a new or
progressive opacity.
Patients were excluded from the trial if they met
any of the following criteria: a history of allergy to
carboxyquinolone or macrolide derivatives; preg-
nant or nursing women; severe hepatic impairment
(baseline SGOT or SGPT, and/or total bilirubin X3
times the upper limit of normal); co-existent
disease considered likely to affect the outcome of
the study (e.g., lung cancer, lung abscess, collagen
vascular disease affecting the lungs, empyema,
cystic fibrosis, known or suspected active tubercu-
losis, alcoholism); use of systemic corticosteroids
415mg per day oral prednisone (or its equivalent).
Diagnostic workup
Two sets of blood cultures, sputum for culture and a
sample of clotted blood for serology were collected
at enrollment. Additional specimens for serological
testing were collected at the 2- and 6-week follow-
up visits.
Laboratory methods
Blood and sputum were processed for culture at the
hospital microbiology laboratory of the site inves-
tigator. Only sputum samples with p10 squamous
epithelial cells per low power field and X25
leucocytes per low power field were processed for
culture. Standard methods were used for isolation
and identification of microorganisms.
Serology
All serum samples were tested at a central
laboratory.
Serum samples (acute phase, 14 and 42 day)
were received frozen on dry ice. Prior to testing,
samples were thawed and then centrifuged at
3000g for 10min.
Antimicrobial susceptibility testing
This testing was performed at each site using
standard methods.
Chlamydia pneumoniae IgG and IgM
Samples were tested using a qualitative enzyme-
linked immunosorbent assay (ELISA) (Savyon Diag-
nostics Ltd., Ashdod, Israel) according to the
manufacturer’s instructions. Results were ex-
pressed as the cut-off index which is equal to the
absorbance of the patient’s serum sample at
450 nm divided by twice the absorbance of the
negative control at 450 nm. A cut-off index of less
than 1 was considered negative and a value of
greater than 1.1 was considered as positive. Values
between 1 and 1.1 were considered borderline.
Results of enrollment, day 14 and 6-week follow-up
serum were interpreted based on both the IgG and
IgM results as follows:
IgG IgM Interpretation
Negative Negative No evidence of infection
Negative Positive Recent/current infection
Positive Positive Recent/current infection
Positive Negative Past infection
Mycoplasma pneumoniae IgG and IgM
Serum samples were tested using a semi-quantita-
tive enzyme-linked immunosorbent assay (ELISA)
(Savyon Diagnostics Ltd., Ashdod, Israel) according
to the manufacturer’s instructions. A standard
curve was generated for each assay using the
calibrators provided by the manufacturer. The
absorbance values of the patient samples were
then plotted on the standard curve and the
concentration of antibodies interpolated and ex-
pressed as binding units per ml (BU/ml). Patients
with BU/ml values of 415 were considered
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positive. Results of pre-study, day 14 and 6-week
follow-up serum were interpreted based on both
the IgG and IgM results as follows:
IgG IgM Interpretation
Negative Negative No evidence of infection
Negative Positive Recent/current infection
Positive Positive Recent/current infection
Positive Negative Past infection
Patients with negative serology at Pre-Study but
whose IgG and/or IgM became positive at day 14 or
6-week follow-up were considered as having re-
cent/current infection.
Sputum culture interpretation
All sputum culture results were interpreted in
conjunction with Gram stain results. In particular
any aerobic Gram negative bacillus that was
considered a pathogen had to be present on Gram
stain.
Results
The study population as described in Table 1 was
young with a mean age of 47.8 years and most had
pneumonia of mild severity. One patient who had
small cell carcinoma of the lung died. Almost 8% of
the study population required subsequent admis-
sion to hospital, with half of these patients
requiring admission because of the pneumonia
and the remainder because of worsening of
comorbidities. The results of blood cultures are
given in Table 2. Note that only 1.4% were positive
and that all isolates were Streptococcus pneumo-
niae. One patient had yeast isolated from the blood
which was felt to be a contaminant. This person
had serological evidence of acute infection with
Mycoplasma pneumoniae. Three of the seven
patients with pneumococcal bacteremia were
admitted to hospitalFtwo for worsening pneumo-
nia and one for sepsis. All of the S. pneumoniae
isolates were susceptible to clarithromycin and
moxifloxacin. Three were susceptible to penicillin
and one was intermediately resistant and another
was resistant. Penicillin susceptibility results were
not available for two isolates.
Table 3 gives the sputum culture results. Only
47.5% had a sputum specimen obtained and 37.7% of
these were positive for a respiratory pathogen.
Overall 75 (15%) of patients had a positive sputum
culture. One of the patients who had S. pneumoniae
isolated from the sputum also had this microorgan-
ism isolated from the blood.
Table 4 gives the results of the serological
testing. Fifteen percent had M. pneumoniae pneu-
monia and 12% had Chlamydia pneumoniae pneu-
monia. A small number, 11 (2.5%), met the criteria
for dual infection with these pathogens. It is
noteworthy than 9 of the 11 were positive for C.
pneumoniae and M. pneumoniae IgM antibodies at
the time of enrollment. For the remaining two, one
was positive for C. pneumoniae at the time of
enrollment and M. pneumoniae was positive at the
2-week follow-up visit. The reverse was true for
the other.
Overall an etiological diagnosis was made in
48.4% (Table 5). M. pneumoniae, C. pneumoniae
and S. pneumoniae were the three most common
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Table 1 Characteristics of the study population.
Number of patients 507
N(%) male 263
(51.9%)
Age (years) mean (SD) 47.8 (16.2)
FINE class
I 286(56.4%)
II 150
(29.6%)
III 64 (12.6%)
IV 7(1.4%)
Subsequent hospitalization
Respiratory related N(%) 20(3.9%)
Non-respiratory related N(%) 20(3.9%)
N (%) deaths 1(0.2%)
Systolic blood pressureFmean (SD) 125.6
(18.0)
Diastolic blood pressureFmean (SD) 75.1 (10.9)
Heart rate (BPM)Fmean (SD) 88.8 (17.2)
Respiration rateFmean (SD) 21.1 (4.2)
Temperature(1C)Fmean (SD) 37.3 (1.0)
Hemoglobin (g/l)Fmean (SD) 134.7
(15.5)
White blood cell count (giga/l)F
mean (SD)
10.5 (5.4)
Platelet count (giga/l)Fmean (SD) 270.9
(91.2)
Table 2 Blood culture results.
No. of patients 507
No. (%) with blood cultures done 419 82%
No. (%) with blood cultures positive
for a pathogen
7 1.4%
Organism isolated from blood
S. pneumoniae 7
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pathogens. Haemophilus influenzae was surpris-
ingly common at 4.9%.
Discussion
This study has several important findings. The first
is that an etiological diagnosis was made in only
half the patients. The rank order of the pathogens,
M. pneumoniae, C. pneumoniae and S. pneumoniae
is similar to that found in other studies.7–10 Indeed
in all studies including the present one M.
pneumoniae was the most commonly identified
pathogen, accounting for 17–34% of all cases. M.
pneumoniae undergoes cyclical variation with
peaks every 4–7 years,11 thus it is not surprising
that the rate of M. pneumoniae as a cause of
ambulatory CAP will vary from study to study.
In the two studies in which C. pneumoniae was
sought7,10 and the current study, 5.3%, 10.7% and
12% were felt to have pneumonia due to this
pathogen. In our study 11 patients had dual
infection with M. pneumoniae and C. pneumoniae.
Whether this represents dual infection or antibody
cross reactivity is a question that needs to be
addressed. In one study the sensitivity and speci-
ficity of the EIA test that we used for the detection
of M. pneumoniae IgM and IgG antibodies was
100%12 while the sensitivity and specificity of the C.
pneumoniae test was 92% and 95%, respectively.13
Bochud et al.14 carried out a comprehensive
study of the etiology of pneumonia in 184 patients
with ambulatory pneumonia. An etiological diag-
nosis was made in 45.9%. S. pneumoniae was most
common, followed by M. pneumoniae, Chlamydia
species and Influenza A virus.
The second important finding in our study is the
low rate of bacteremia at 1.4% and the observation
that all of the isolates were S. pneumoniae. The
population in this study reflects that seen in clinical
practice in that most were recruited from physi-
cians’ offices and some from Emergency Rooms. In a
study of 236 patients with lower respiratory tract
infections in Nottingham, UK, 37% of whom had
radiological evidence of pneumonia only 1 of 219
(0.5%) had a positive blood culture.15 In Bochud’s
study of 184 patients only six had S. pneumoniae
isolated from the blood.14 The number of patients
with positive blood cultures is not stated in the
paper but if these were the only ones with positive
blood cultures the positivity rate would be 3%.
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Table 3 Sputum culture results.
No. of patients 507
Sputum sample obtained 241
47.5%
Not processed 6 1.1%
No. of patients with a positive
sputum culture
75 31%
Organisms isolated from sputum
Normal flora 92 38%
No growth 68 28%
H. influenzae 25 10%
S. pneumoniae 24 10%
H. parainfluenzae 10 4%
S. aureus 6 2.5%
Moraxella catarrhalis 6 2.5%
Streptococcus species 5 2%
Klebsiella pneumoniae 2 0.8%
Acinetobacter spp 2 0.8%
Streptococcus pyogenes 1
Streptococcus agalactiae 1
Neisseria meningitidis 1
Escherichia coli
Enterobacter cloacae 1
Enterbacter aerogenes 1
Pseudomonas aeruginosa 1
Agrobacterium radiobacter 1
Haemophilus parahaemolyticus 1
Pasteurella multocida 1
Some patients had more than 1 microorganism isolated.
Table 4 Results of testing serum samples for
antibodies to M. pneumoniae and C. pneumoniae.
No. of patients 507
No. with acute and convalescent
serology
437 86.2%
No. with acute phase serology
only
67 13.2%
No. with M. pneumoniae 76 15%
No. with C. pneumoniae 61 12%
No. with both 11 2.5%
Table 5 Etiology of pneumonia in 507 ambulatory
patients.
Unknown 262 51.6%
M. pneumoniae 76 15%
C. pneumoniae 61 12%
Both C. pneumoniae and M.
pneumoniae
11 2.1%
S. pneumoniae 30 5.9%
H. influenzae 25 4.9%
H. parainfluenzae 10 1.9%
S. aureus 6 1.1%
Moraxella catarrhalis 6 1.1%
Streptococcus species 5 0.9%
Other 14 2.8%
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Campbell et al.16 studied 289 patients with CAP
who were seen in an Emergency Room setting and
treated on an ambulatory basis. Six (2.1%) had
positive blood culturesF4 were S. pneumoniae and
2 Escherichia coli. Three of the six were subse-
quently admitted to hospital.
H. influenzae accounted for 4.9% of the pneu-
monias in our study. It was uncommon in Bochud’s
study14 at 1.8%. In contrast in a study of 610
patients with CAP attending primary care clinics in
the United States 12.6% had H. influenzae isolated
from sputum.17 This latter population was char-
acterized by a history of chronic obstructive
pulmonary disease in 18% or current tobacco
smokers at 34%. Patients with chronic obstructive
pulmonary disease frequently carry H. influenzae in
their respiratory secretions.18 Unfortunately, there
have been no studies of H. influenzae pneumonia
that define the risk factors associated with certain
patient characteristics.19
Haemophilus parainfluenzae accounted for 4% of
the cases of pneumonia. This microorganism has
not been reported with this frequency in many
other studies of CAP.1–3 Haemophilus bacteria
constitute approximately 10% of the normal bac-
terial flora of the healthy upper respiratory tract
and H. parainfluenzae accounts for 75% of the
Haemophilus flora both in the oral cavity and in the
pharynx but is absent from the nasal cavity.20 Thus
it is possible that the isolation of H. parainfluenzae
represent colonization rather than infection. How-
ever, there are well documented cases of H.
parainfluenzae pneumonia.21,22 In a recent study
carried out in 15 countries H. parainfluenzae
accounted for 2.2% of the pneumonias and 10% of
the patients who had sputum submitted for
culture.23
Staphylococcus aureus was the fifth most com-
mon cause of pneumonia in our study accounting
for 2.5% of the cases. In Hoeffken’s study 23 it
accounted for about 1% of the cases and ranked in
the 9th position. In three other studies S. aureus
was not mentioned as a cause of ambulatory
CAP.8,14,15
Nine patients had aerobic gram negative bacteria
isolated from sputum and using our criteria these
agents were felt to be the cause of the pneumonia.
Pneumonia due to these bacteria is usually hospital
acquired 24 or is present in the setting of aspiration
in elderly patients.25,26 Any severe illness predis-
poses to colonization of the oropharynx with
aerobic gram negative bacilli 27 thus the recovery
of these organisms may represent colonization of
the upper airway in patients who were ill for
several days prior to presentation. In a review of
the changes in etiology of pneumonia that have
occurred over the past two decades Kayser noted
that Enterobacteriaceae and S. aureus are now
seen more frequently as causes of CAP.28
We performed serological studies for M. pneu-
moniae and C. pneumoniae only. Studies that
performed a battery of serological tests have found
that Influenza viruses A and B, respiratory syncytial
virus, adenovirus, Coxiella burnetii, C. psittaci,
and Legionella species account for a small but
definite number of cases of CAP treated on an
ambulatory basis.7,8,14 Thus more comprehensive
testing may have allowed us to diagnose 10–15%
more of the cases of pneumonia, leaving 35–40% of
the cases as of unknown etiology.
The issue of antimicrobial resistance is of
concern when choosing therapy on an empiric
basis. Zhanel et al.29 collected a total of 6991
unique patient isolates of S. pneumoniae from
October 1997 to June 2002 from 25 medical centers
in 9 of the 10 Canadian provinces. They found that
20.2% were penicillin non-susceptible, with 14.6%
being penicillin intermediate (MIC, 0.12–1 mg/ml)
and 5.6% being penicillin resistant (MIC,4/¼ 2 mg/
ml). Almost 10% of the isolates were resistant to
macrolides. Overall resistant to the quinolones was
low with 0.3% of the strains being resistant to
moxifloxacin and 0.6% resistant to levofloxacin and
gatifloxacin.29 These rates increased to 1.2% for the
penicillin non-susceptible strains. The same authors
also tested 7566 unique patient isolates of H.
influenzae and 2314 unique patient isolates of M.
catarrhalis and found that 1.6% of the H. influenzae
were resistant to clarithromycin and 0.1% to
moxifloxacin.30 All of the M. catarrhalis isolates
were susceptible to both moxifloxacin and clari-
thromycin. In our study all of the bacteremic
S. pneumoniae isolates were susceptible to clari-
thromycin and moxifloxacin.
Our study has several strengths and limitations.
The strengths are the large number of patients
studied and enrollment from multiple sites in
Canada. The limitations are that we did not test
urine samples for Legionella and S. pneumoniae
antigens. We also did not do a comprehensive
serological work-up.
In conclusion, we have shown that despite
considerable efforts an etiological diagnosis of
community-acquired pneumonia in an ambulatory
setting is made in only half the patients.
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